$Rhythm Pharmaceuticals, Inc.(RYTM)$ From Cowen - publication of longer-term Ph II data in LEPR deficiency showing sustained weight reduction&good tolerability out to 61 weeks.Continue to think that RYTM is undervalued for setmelanotide’s potential,expect it outperform as setmelanotide’s development progresses. Rhythm expects to announce initial data from its ongoing Phase 2 proof-of-concept basket study of setmelanotide in each of Alström Syndrome, POMC epigenetic disorders, and POMC heterozygous deficiency obesity in the first half of 2018. Big mover coming up!